Pegfilgrastim

From Wikipedia, the free encyclopedia
  (Redirected from Neulasta)
Jump to: navigation, search
Pegfilgrastim
Clinical data
Trade names originally Neulasta, other brand names worldwide[1]
AHFS/Drugs.com Monograph
MedlinePlus a607058
Pregnancy
category
  • US: C (Risk not ruled out)
ATC code
Legal status
Legal status
Pharmacokinetic data
Biological half-life 15–80 hrs
Identifiers
CAS Number
IUPHAR/BPS
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
ECHA InfoCard 100.169.155
Chemical and physical data
Formula C845H1343N223O243S9 + PEG
Molar mass 39,000 g/mol
 NYesY (what is this?)  (verify)

Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim. It serves to stimulate the level of white blood cells (neutrophils).[2]

Pegfilgrastim treatment can be used to stimulate bone marrow to produce more neutrophils to fight infection in patients undergoing chemotherapy.[3]

Pegfilgrastim has a human half-life of 15 to 80 hours, much longer than the parent filgrastim (3–4 hours).[4][3]

In the United States as of 2015 the branded form costs between $5,327 and $8,191 a dose.[5]

Biosimilars[edit]

In July 2016 the US FDA rejected a biosimilar application from Sandoz.[6]

In 2016 Coherus BioSciences is running clinical studies on its own pegfilgrastim biosimilar CHS-1701.[6]

References[edit]

  1. ^ Drugs.com International brand names for pegfilgrastim Page accessed April 1, 2016
  2. ^ Walsh, G, Spada, S. "Epogen/Procrit" in: Directory of approved biopharmaceutical products. CRC Press, 2005, pp. 136–37.
  3. ^ a b Drugs.com: Pegfilgrastim
  4. ^ Ho, R.J.Y., Gibaldi, M. Biotechnology and biopharmaceuticals: transforming proteins and genes into drugs Wiley-IEEE, 2003, pp. 139, 158.
  5. ^ Langreth, Robert (June 29, 2016). "Decoding Big Pharma's Secret Drug Pricing Practices". Bloomberg. Retrieved 15 July 2016. 
  6. ^ a b US FDA rejects Sandoz’s Neulasta biosimilar. 19 July 2016

External links[edit]